News

HemoShear Therapeutics Hiring Senior Assay Scientist

ABOUT THE JOB

SUMMARY OF POSITION:

The Lab Scientist will design, develop and perform biological assays while also analyzing data and presenting their results as a member of HemoShear’s proprietary and collaborative partnership drug discovery program teams. The Lab Scientist will be expected to work independently in a self-directed manner as well as collaboratively alongside a larger assay team. Additional responsibilities include performing cell culture, molecular biology experiments to generate novel biological reagents, and protein production and purification. The role will require training of colleagues in the developed techniques to support the HemoShear assay team. The position involves teamwork, high levels of communication, and ensuring scientific excellence. The laboratory Scientist will work closely with the program team leaders to ensure that all work stays on schedule and is completed according to HemoShear’s standards.

WHAT YOU’LL DO:

  • Develop and optimize cell-free and cell-based assays in medium- to high-throughput (96/384-well) formats
  • Generate stable cell lines and verify expression or lack of expression using molecular biology endpoints, western blots and reporter assays using various readouts (e.g., qPCR, fluorescence, luminescence, mass spectrometry, etc.)
  • Protein production, purification, and characterization.
  • Validate assays using defined chemical matter
  • Deliver defined biomarker assays with clinical relevance.
  • Proactively analyze experimental data and integrate disparate data from other experiments, literature, and other colleagues to make informed decisions to improve existing or develop new assays
  • Partner with chemistry and biology teams to troubleshoot through technical and scientific challenges to deliver critical data.
  • Present results, conclusions, and implications to project teams and senior management.

ABOUT YOU

  • M.S. with 5+ years’ experience, or Ph.D. with 2+ years’ industrial experience.
  • Experience in cellular and molecular biology (DNA/RNA extraction, RT-qPCR, ddPCR, qPCR, primer design), cell-based assays (sterile tissue culture techniques, transfection, transduction, maintaining, subcloning, and banking cells).
  • Experience measuring protein expression levels, turn-over and synthesis rates: western blot, ELISA, reporter assays, etc.
  • Strength in experimental design, execution, and data analysis using multiple assay platforms working with various cell systems
  • Experience using automated liquid handlers, plate readers and associated software
  • Expertise in cell biology, molecular biology, biochemistry with emphasis on small molecules interactions
  • Experience in mass spectrometry is a plus
  • Experience with RNAi and CRISPR is a plus
  • Must be a self-starter, proactive, co-operative, and proficient at working both independently and in a small team environment
  • Strong verbal and written communication skills

To apply: https://www.linkedin.com/jobs/view/2502250117/?refId=I1d6O6CjQR%2BcDhrLD9dfXQ%3D%3D

Recent News

10/21/2025

SRI multi-party team selected as an awardee by ARPA-H to develop at-home screening for ≥30 types of cancers

SRI, along with research partners Foothold Labs and Triple Ring Technologies and commercial partner Beacon Dx Health, has been awarded up to $34 million from the Advanced Research Projects Agency for Health (ARPA-H) to develop technology as part of the POSEIDON (Platform Optimizing SynBio for Early Intervention and Detection in Oncology) program. This pioneering program

10/21/2025

Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead product candidate, QRX003, for the treatment of Netherton Syndrome. The designation follows previously granted Orphan

10/20/2025

Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the start of construction for a $3 billion, 400,000-square-foot pharmaceutical manufacturing facility at its Elkton, Virginia, site. Merck’s investment in the Center of Excellence for Pharmaceutical Manufacturing is part of a more than $70 billion investment beginning in 2025 to